Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer

Efficace, Fabio; Biganzoli, Laura; Piccart, Martine; Coens, Corneel; Steen, Kristel Van; Čufer, Tanja; Coleman, Robert E.; Calvert, Hilary; Gamucci, Teresa; Twelves, Chris; Fargeot, P.; Bottomley, Andrew

doi:10.1016/j.ejca.2004.01.014

Cited by 143 publications

(109 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another meta-analysis using data from 30 cancer trials produced a multivariable model that identified impaired physical functioning, pain and appetite loss as independent predictors of survival in addition to established biomedical factors (Quinten et al, 2009). Individual trials in advanced breast cancer have shown similar findings with PWB (Coates et al, 1992), appetite loss (Efficace et al, 2004), pain (Kramer et al, 2000) and overall QL (Seidman et al, 1995;Winer et al, 2004) all reported as independent predictors of survival. This study validates the prognostic significance of self-reported QL, and specifically of PWB and appetite, as predictors of survival in advanced breast cancer.…”

Section: Discussionmentioning

confidence: 50%

“…Poor QL before treatment is associated with shorter survival in patients with advanced breast cancer (Coates et al, 1992;Efficace et al, 2004;Winer et al, 2004;Gotay et al, 2008). However, there is only limited evidence of the relationship between baseline QL and response to chemotherapy (Seidman et al, 1995;Kramer et al, 2000;Winer et al, 2004) and treatment-related toxicity.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Baseline health-related quality of life (QL) is associated with survival in advanced breast cancer. We sought to identify patients who were less likely to respond to chemotherapy and at greater risk of toxicity on the basis of their QL. METHODS: We used data from three advanced breast cancer trials in which patients (n ¼ 378) were treated with cyclophosphamide, methotrexate and 5-fluouracil. Patients self-rated their QL using LASA scales for physical well-being (PWB), mood, pain, nausea/ vomiting, appetite and overall QL. Multivariable regression models were constructed to compare overall survival (OS), objective tumour response (OTR), adverse events (AEs) and weight loss according to grouped QL scores. RESULTS: Physical well-being, mood, appetite and overall QL were significant univariable predictors of OS. Physical well-being and appetite remained significant after adjustment for baseline biomedical factors. Poor PWB was associated with lower OTR (odds ratio (OR) ¼ 0.21, 95% confidence interval (CI) 0.09 -0.51), higher risk of non-haematological AEs (OR ¼ 3.26, 95% CI 1.49 -7.15) and greater risk of weight loss (OR 2.37, 95% CI 1.12 -5.01) compared with good PWB. CONCLUSIONS: In women with advanced breast cancer, PWB and appetite are predictors of chemotherapy response and toxicity as well as survival. Quality of life should be a routine clinical assessment to guide patient selection for chemotherapy and for stratification of patients in clinical trials.

show abstract

Section: Discussionmentioning

confidence: 50%

mentioning

confidence: 99%

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Women with metastatic disease have a relatively short expected survival time. Thus, the impact on health related quality of life (HRQoL) is an important factor to consider when making decisions about treatment at this stage of disease [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Svensson

Einbeigi

Johansson

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…6,[11][12][13][14] In rectal cancer, in which acute GI symptoms frequently are observed clinically, few studies have examined PROs. In the current study, we prospectively collected patient-reported GI symptoms weekly during chemoradiation treatment to demonstrate the feasibility of incorporating PRO measurements into clinical practice and to describe the trajectory of symptom development.…”

mentioning

confidence: 99%

Patient‐reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer

Chen

Mamon

Chen

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:Although it is known that standard 5-fluorouracil-based chemoradiation therapy for rectal cancer causes significant acute gastrointestinal (GI) toxicity, research on patient-reported outcomes (PROs) is limited. The authors undertook the current study to assess the feasibility of incorporating PRO measurement into routine clinical practice and to describe the trajectory of symptom development during treatment. METHODS: Seventy-seven consecutive patients who were treated between 2006 and 2008 were eligible. Patients completed the 7-item Bowel Problems Scale immediately before weekly physician visits. RESULTS: The questionnaire completion rate was 95%. Individual GI symptoms had different trajectories of development. By Week 5, approximately 40% of all patients developed clinically meaningful pain, bowel urgency, or tenesmus that was not present during Week 1; 30% developed diarrhea, abdominal cramping, and passing mucus. However, overall symptom burden was moderate. Seventyfive percent of patients who presented with rectal bleeding at Week 1 improved by Week 3 of treatment. Within each physician-assessed grade of diarrhea, patient experience varied widely. For example, of the 50 patients who developed grade 2 diarrhea on the Radiation Therapy Oncology Group Acute Morbidity Scale, the numbers of patients reporting only occasional symptoms versus those reporting frequent or very frequent symptoms were similar. CONCLUSIONS: PROs provided information on patient symptoms during chemoradiation treatment for rectal cancer that was not captured otherwise, and it was feasible to incorporate PROs into routine clinical practice. The current results may be used by physicians to counsel their patients before treatment initiation and to provide a benchmark against which trials that use new therapies may be compared.

show abstract

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer

Cited by 143 publications

References 43 publications

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Patient‐reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer

Contact Info

Product

Resources

About